Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SFA002 vs Apremilast in Plaque Psoriasis
NCT06863493Phase 3Not yet recruiting
- Sponsor
- SFA Therapeutics
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of SFA-002 in plaque psoriasis, sponsored by SFA Therapeutics. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
SFA-002
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06863493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06863493.